Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostication and Biomarker Potential of C26:0 Lysophosphatidylcholine in Adrenoleukodystrophy

10 Feb 2025

Abstract excerpt

This cohort study conducted among Minnesota children diagnosed with adrenoleukodystrophy through newborn screening examines correlation of C26:0 lysophosphatidylcholine (C26LPC) with clinical phenotype over 5 years and recommends adjusting early childhood surveillance regimens in children with lower C26LPC levels.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hyperglycemia and glycemic control in critically ill and hospitalized patients
Share to Metabolism and Genetic Disorders
Share to Peroxisome Proliferator-Activated Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39928311
DOI: 10.1001/jamapediatrics.2024.6774

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostication and Biomarker Potential of C26:0 Lysophosphatidylcholine in AdrenoleukodystrophyPMID 39928311Read ↗

Newborn Screening for X-Linked Adrenoleukodystrophy (X-ALD): Biochemical, Molecular, and Clinical Characteristics of Other Genetic ConditionsSemantic proximity Read ↗

Insights From Minnesota on Newborn Screening for Adrenoleukodystrophy: A 5-Year Update.Semantic proximity Read ↗

A report on state‐wide implementation of newborn screening for X‐linked AdrenoleukodystrophySemantic proximity Read ↗

Evaluation of C26:0‐lysophosphatidylcholine and C26:0‐carnitine as diagnostic markers for Zellweger spectrum disordersSemantic proximity Read ↗

Newborn Screening for X-Linked Adrenoleukodystrophy in Nebraska: Initial Experiences and ChallengesSemantic proximity Read ↗

Molecular Biomarkers for Adrenoleukodystrophy: An Unmet NeedSemantic proximity Read ↗

Disease Outcomes in Boys with <i>ABCD1</i> Variants Identified by Newborn Screening for X-ALDSemantic proximity Read ↗

The Grey Zone Project: Risk‐Based Classification of ABCD1 Variants in X‐Linked AdrenoleukodystrophySemantic proximity Read ↗

Sex‐specific newborn screening for X‐linked adrenoleukodystrophySemantic proximity Read ↗

Neonatal detection of Aicardi Goutières Syndrome by increased C26:0 lysophosphatidylcholine and interferon signature on newborn screening blood spots.Semantic proximity Read ↗

Drug discovery for X-linked adrenoleukodystrophy: An unbiased screen for compounds that lower very long-chain fatty acids.Semantic proximity Read ↗

Natural History of Clinical Phenotypes and Their Biochemical Correlates in Adult X-Linked Adrenoleukodystrophy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.